AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16355944
Drug: ketamine, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine, 0.5 mg/kg
Trial: 16355944
Drug: saline, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline, 2 mL
Trial: 16355944
Drug: ketamine, 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine, 1.2 mg/kg
Trial: 9706940
Drug: Topical lidocaine-prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine-prilocaine cream (EMLA)
Trial: 7876652
Drug: Inactivated HAV
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 2 months (Group A)
Trial: 7876652
Drug: Inactivated HAV
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated HAV vaccine, 0.5 mL, with second and third doses at 1 and 6 months (Group B)
Trial: 2213800
Drug: Dimethicone/antacid (Asilone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethicone/antacid (Asilone Gel)
Trial: 2213800
Drug: Alginate/antacid (Gaviscon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate/antacid (Gaviscon liquid)
Trial: 28803333
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg TLV
Trial: 28803333
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg TLV
Trial: 28803333
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg TLV
Trial: 24917527
Drug: Psychological intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychological intervention and oral health education before and after treatment
Trial: 24917527
Drug: Regular doctor's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular doctor's advice after treatment (Control)
Trial: 21178180
Drug: Crystalline l-Thr
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalline l-Thr added to basal diet (60% of NRC recommendation in Exp. 1 and 20-60% in Exp. 2)
Trial: 19414053
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose alcohol (0.2 g/kg)
Trial: 19414053
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose alcohol (0.4 g/kg)
Trial: 12151972
Drug: Fludarabine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (25 mg/m2 intravenously on days 1-5) followed by interferon-α-2a (2 × 106 U/m2 subcutaneously on days 22-26)
Trial: 2726771
Drug: Chimeric monoclonal
RxNorm normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric monoclonal antibody (mAb) 10 mg single infusion
Trial: 2726771
Drug: Chimeric monoclonal
RxNorm normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric monoclonal antibody (mAb) 40 mg single infusion
Trial: 2726771
Drug: Chimeric monoclonal
RxNorm normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric monoclonal antibody (mAb) 10 mg three infusions
Trial: 2726771
Drug: Chimeric monoclonal
RxNorm normalized name: Chimeric monoclonal antibody to mesothelin
DrugBank: Amatuximab (DB12845)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric monoclonal antibody (mAb) 40 mg three infusions
Trial: 29512827
Drug: 170 mug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 170 mug LPP administered subcutaneously over 3 weeks
Trial: 24359543
Drug: Complex intervention
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex intervention for GPs including interactive workshops, audit and feedback reports, automated electronic prompts, and a recommendation for delayed antimicrobial treatment.
Trial: 18387160
Drug: Sevelamer (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer (3.0 g/day)
Trial: 18387160
Drug: Sevelamer with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer with CaCO3 (3.0 g/day)
Trial: 18387160
Drug: Colestimide with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestimide with CaCO3 (3.0 g/day)
Trial: 16343856
Drug: Ciprofloxacin XR
RxNorm normalized name: ciprofloxacin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin XR 1000 mg
Trial: 9391723
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of heparin based on initial patient-specific dose per unit weight and adjustments during CPB based on reference heparin concentration.
Trial: 9391723
Drug: Monitoring group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring group using bolus administration of heparin calculated by the Hepcon instrument during CPB.
Trial: 9391723
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received similar doses of heparin and protamine, and had similar transfusion requirements.
Trial: 7933485
Drug: Intrathecal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal buprenorphine (0.05 mg)
Trial: 7933485
Drug: Intrathecal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal buprenorphine (0.075 mg)
Trial: 3328281
Drug: Sucralfate treatment
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate treatment
Trial: 30698458
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolant spray prior to SC heparin injection
Trial: 30698458
Drug: Water spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water spray (placebo) prior to SC heparin injection
Trial: 22321976
Drug: Non-exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-exercise group (daily activities).
Trial: 16922471
Drug: Short-term donepezil
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term donepezil therapy (3 months)
Trial: 16922471
Drug: Long-term donepezil
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term donepezil therapy (1 year)
Trial: 9222672
Drug: 500 U/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 U/kg of r‐HuEPO divided in three doses (300 U/kg 12 days before surgery, 100 U/kg 4 and 8 days later)
Trial: 9222672
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (r‐HuEPO treatment)
Trial: 3616754
Drug: Narcotic analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic analgesic (meperidine hydrochloride) plus antispasmodics (diazepam and baclofen)
Trial: 3616754
Drug: Narcotic analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcotic analgesic (meperidine hydrochloride) alone
Trial: 23635616
Drug: Minimal residue
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal residue diet plus mechanical bowel preparation with oral sodium picosulphate
Trial: 23635616
Drug: Minimal residue
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal residue diet plus mechanical bowel preparation
Trial: 17884341
Drug: Tri E
RxNorm normalized name: Evernia prunastri extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tri E Tocotrienol 160 mg daily for 6 months
Trial: 11203592
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no EDTA gel)
Trial: 9337677
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon (IFN)
Trial: 8409113
Drug: Aspartame (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (50, 300, 600 mg doses; half doses for subjects weighing less than 40 kg)
Trial: 3531314
Drug: Cimetidine 1
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 1 g daily for 5 weeks
Trial: 25884778
Drug: Diclegis® (doxylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclegis® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg)
Trial: 15175031
Drug: Anti-IL-5 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-IL-5 monoclonal antibody (mepolizumab)
Trial: 11305700
Drug: Nefazodone, average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefazodone, average end‐of‐treatment dose 376 mg/day
Trial: 15251769
Drug: 70/30 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70/30 insulin (premixed 30% regular insulin and 70% NPH insulin), administered twice daily for 4 weeks
Trial: 15251769
Drug: NPH insulin,
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin, administered twice daily for 4 weeks
Trial: 15251769
Drug: 70/30 insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70/30 insulin (premixed 30% regular insulin and 70% NPH insulin)
Trial: 25853533
Drug: Home visits
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home visits conducted by family medicine residents
Trial: 23740935
Drug: Neoadjuvant docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant docetaxel and GVAX therapy
Trial: 19665354
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (n=6) - roughened implant surface by sandblasting only
Trial: 19665354
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (n=12) - implant surface with additional macroretentions
Trial: 11759182
Drug: PDRN (5625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDRN (5625 mg/vial) administered intramuscularly once daily and subcutaneously (2 vials every 3 days) for 10 days
Trial: 11759182
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intramuscularly once daily and subcutaneously (2 vials every 3 days) for 10 days
Trial: 3277419
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg once daily
Trial: 3277419
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 to 50 mg twice daily
Trial: 31018682
Drug: Dipeptidyl peptidase-4
RxNorm normalized name: Immature tripeptidyl-peptidase I
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dipeptidyl peptidase-4 inhibitors
Trial: 25955246
Drug: Agalsidase beta
RxNorm normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Agalsidase beta (two doses)
Trial: 16846545
Drug: RSV 10
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV 10 mg/day
Trial: 16846545
Drug: RSV 10
RxNorm normalized name: RSV-IGIV
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV 10 mg/day and ATV 20 mg/day
Trial: 12775859
Drug: Baseline lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline lung function and bronchodilator responsiveness measured using impulse oscillometry (IOS)
Trial: 11588893
Drug: Single supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single supplements of vitamin C or E
Trial: 11588893
Drug: Antioxidant mixtures
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant mixtures or single supplements of vitamins A and D, zinc, or beta-carotene
Trial: 11588893
Drug: Vitamins A,
RxNorm normalized name: vitamins A,C,and D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins A, C, and D intake from supplements
Trial: 11588893
Drug: Beta-carotene, folate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene, folate, and zinc intake from supplements
Trial: 9614950
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy and radiotherapy
Trial: 7863731
Drug: Mebendazole (Janssen)
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole (Janssen) given twice daily for three days
Trial: 7863731
Drug: Mebendazole (Janssen)
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole (Janssen) single-dose treatment
Trial: 2491829
Drug: Oral lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lithium carbonate 1200 mg daily
Trial: 29106693
Drug: Individualized metacognitive
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized metacognitive therapy (MCT+)
Trial: 26526324
Drug: High number
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High number of different sexual partners (vaginal and oral)
Trial: 16029401
Drug: i.v. paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. paracetamol 15 mg.kg(‐1)
Trial: 16029401
Drug: propacetamol 30
RxNorm normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propacetamol 30 mg.kg(‐1)
Trial: 12505969
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of 2% lidocaine sprayed down the ETT 5 min before extubation (Group 2)
Trial: 12505969
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug (Group 1)
Trial: 12212217
Drug: Propofol 1
RxNorm normalized name: propofol 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1 mg.kg‐1 combined with Ketamine
Trial: 25135803
Drug: Pharmacist intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist intervention in a monitoring program for CKD patients, including daily follow-up and recommendations for dose adjustments of nephrotoxic drugs.
Trial: 7756047
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pre-treatment alkaline phosphatase and alkaline phosphatase half-life
Trial: 7756047
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pre-treatment hydroxyproline and hydroxyproline half-life
Trial: 2319516
Drug: Intravenous 'minipulse'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 'minipulse' (100 mg) methylprednisolone (MP) therapy
Trial: 2319516
Drug: Standard pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pulse (1000 mg) methylprednisolone (MP) therapy
Trial: 583022
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg treptilamine i.v.
Trial: 583022
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg treptilamine p.o.
Trial: 31866190
Drug: Dantrolene (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dantrolene (1 cap, 25 mg three times daily, or two times daily if not tolerable)
Trial: 18707785
Drug: Low boost
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low boost dose of 10 Gy
Trial: 18707785
Drug: High boost
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High boost dose of 26 Gy
Trial: 11735866
Drug: Short course
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short course of i.v. ampicillin, gentamicin, and clindamycin followed by p.o. amoxicillin and clavulanate potassium plus metronidazole (n = 16)
Trial: 11735866
Drug: Conversion to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversion to oral therapy
Trial: 8172790
Drug: Vinorelbine (NVB)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (NVB) 30 mg/m2/week
Trial: 8172790
Drug: Vinorelbine (NVB)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (NVB) 30 mg/m2/week plus Cisplatin (DDP) 80 mg/m2/3 weeks
Trial: 25632741
Drug: Salvia Miltiorrhiza
RxNorm normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia Miltiorrhiza (1 g each time, three times per day till one month after PCI)
Trial: 15124679
Drug: Treosulfan/fludarabine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan/fludarabine (3 x 10 g/m2 of treosulfan with 5 x 30 mg/m2 of fludarabine)
Trial: 15124679
Drug: Treosulfan (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treosulfan (escalated from 3 x 10 to 3 x 12 and 3 x 14 g/m2)
Trial: 10865808
Drug: recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant growth hormone (rhGH) for the first six months
Trial: 10865808
Drug: recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant growth hormone (rhGH) for the second six months
Trial: 10865808
Drug: recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant growth hormone (rhGH) for both groups in the second six months
Trial: 3446162
Drug: Low pH
RxNorm normalized name: yellow phenolphthalein
DrugBank: Phenolphthalein (DB04824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pH intravenous immunoglobulin
Trial: 3446162
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous immunoglobulin
Trial: 21649612
Drug: Tetracycline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (500 mg/day × 14 days/month × 3 months)
Trial: 18022183
Drug: Repeating the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating the solutions
Trial: 8290450
Drug: Povidone-iodine (PVP-I)
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine (PVP-I) ointment
Trial: 11948829
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) preparation
Trial: 30222643
Drug: Fasting only
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting only (FO) preparation
Trial: 25538086
Drug: High-sensitivity troponin
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-sensitivity troponin I (hsTnI) assay (Erenna, 99th percentile 9 pg/ml)
Trial: 16854276
Drug: CHB patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHB patients with HBV DNA > 10^7 copies/ml
Trial: 12727933
Drug: Replacement-dose r‐metHuLeptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replacement-dose r‐metHuLeptin during fasting
Trial: 12727933
Drug: Low-dose r‐metHuLeptin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose r‐metHuLeptin
Trial: 10733492
Drug: Chemotherapy (CTx)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CTx) after MOPP/ABV
Trial: 10733492
Drug: Chemotherapy (CTx)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CTx) after ABVPP
Trial: 8958889
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion at 20-80 micrograms/kg/min
Trial: 8958889
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion with oxygen administration
Trial: 2868581
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg at bedtime for 6 months
Trial: 2868581
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg at bedtime for 12 months
Trial: 28639216
Drug: 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg selexipag (Treatment A)
Trial: 28639216
Drug: 4 paediatric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 paediatric tablets of 50 µg selexipag (Treatment B)
Trial: 24412554
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Nigella sativa L. seeds (NS) once daily for four weeks